Global News and Digital Insights
for the Healthcare Industry

Orion joins hands with Jemincare to formulate non-opioid drug for chronic pain

Jemincare, with the help of Orion, will be furthering the development of their non-opioid drug JMKX000623, an inhibitor of a main sodium channel subtype that balances out pain fibres’ stimulation. Orion corporation has partnered up with Jemincare where the former will be responsible for the international development and marketing rights of the non-opioid drug. This drug will treat acute as well as chronic pain. In addition to royalty payments, Orion will also make an upfront payment of $15 million to Jemincare.

Read More from Pharmaceutical Technology 

Share on facebook
Share on twitter
Share on linkedin